An 8-year retrospective review of human albumin solution use August 2015 to March 2023; Guy's and St Thomas' NHS Foundation Trust.

IF 1.5 4区医学 Q3 HEMATOLOGY

Transfusion Medicine Pub Date : 2025-03-29 DOI:10.1111/tme.13138

Asma Tameez Ud Din, Patrick Harrington, Danaee Anicee, Andrew Retter, Llywelyn Cadman-Davies, Muhammad Sajid Yazdani, Paul Holmes, Vickie McDonald, Susan E Robinson

{"title":"An 8-year retrospective review of human albumin solution use August 2015 to March 2023; Guy's and St Thomas' NHS Foundation Trust.","authors":"Asma Tameez Ud Din, Patrick Harrington, Danaee Anicee, Andrew Retter, Llywelyn Cadman-Davies, Muhammad Sajid Yazdani, Paul Holmes, Vickie McDonald, Susan E Robinson","doi":"10.1111/tme.13138","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study is to critically assess the diverse indications for HAS administration over the past 8 years at a prominent tertiary care institution in the United Kingdom.Background: This is timely and relevant, given recent developments in the field. The International Collaborative Transfusion Medicine Group (ICTMG) issued updated guidance on intravenous albumin use in March 2024, reflecting a shift towards more stringent criteria for its application, which necessitates a re-evaluation of current practices.Method: We conducted a retrospective analysis of the usage of HAS from August 2015 to March 2023. Records of all patients who received HAS during this study period were extracted from the Electronic Patient Records (EPR) of Guys and St Thomas' NHS Foundation Trust London (GSTFT). Data analysis was performed using SPSS version 20.Results: A total of 4816 patients received HAS during the audit period, with 21 231 HAS infusions. The majority of infusions were for 20% HAS, with 16 772 (79% of total) infusions for 20% HAS in 4145 patients. A total of 4459 (21%) infusions were recorded for 4.5 and 5% HAS.Conclusion: Our study provides a comprehensive analysis of albumin utilisation and TPE indications over the past 8 years at our institution, establishing a crucial baseline for refining our practices.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tme.13138","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The objective of this study is to critically assess the diverse indications for HAS administration over the past 8 years at a prominent tertiary care institution in the United Kingdom.

Background: This is timely and relevant, given recent developments in the field. The International Collaborative Transfusion Medicine Group (ICTMG) issued updated guidance on intravenous albumin use in March 2024, reflecting a shift towards more stringent criteria for its application, which necessitates a re-evaluation of current practices.

Method: We conducted a retrospective analysis of the usage of HAS from August 2015 to March 2023. Records of all patients who received HAS during this study period were extracted from the Electronic Patient Records (EPR) of Guys and St Thomas' NHS Foundation Trust London (GSTFT). Data analysis was performed using SPSS version 20.

Results: A total of 4816 patients received HAS during the audit period, with 21 231 HAS infusions. The majority of infusions were for 20% HAS, with 16 772 (79% of total) infusions for 20% HAS in 4145 patients. A total of 4459 (21%) infusions were recorded for 4.5 and 5% HAS.

Conclusion: Our study provides a comprehensive analysis of albumin utilisation and TPE indications over the past 8 years at our institution, establishing a crucial baseline for refining our practices.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Medicine 医学-血液学

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Transfusion Medicine publishes articles on transfusion medicine in its widest context, including blood transfusion practice (blood procurement, pharmaceutical, clinical, scientific, computing and documentary aspects), immunohaematology, immunogenetics, histocompatibility, medico-legal applications, and related molecular biology and biotechnology. In addition to original articles, which may include brief communications and case reports, the journal contains a regular educational section (based on invited reviews and state-of-the-art reports), technical section (including quality assurance and current practice guidelines), leading articles, letters to the editor, occasional historical articles and signed book reviews. Some lectures from Society meetings that are likely to be of general interest to readers of the Journal may be published at the discretion of the Editor and subject to the availability of space in the Journal.